1. In a well-controlled study the clinical efficacy of a single intravenous injection of mexiletine (3mg/Kg) on ventricular premature contractions was compared with that of procainamide (10mg/Kg) using continuous electrocardiographic recordings.
1. In a well-controlled study the clinical efficacy of a single intravenous injection of mexiletine (3mg/Kg) on ventricular premature contractions was compared with that of procainamide (10mg/Kg) using continuous electrocardiographic recordings.
2. Of the 56 subjects studied, 55 were analyzed. These consisted of 28 cases in the mexiletine group and 27 in the procainamide group. The backgrounds of both groups were considered to be equivalent.
3. Effectiveness on VPC ("marked and moderate improvement", as judged by the subcommittee) was seen in 88% of the mexiletine group and 84.6% of the procainamide group. This difference was not significant. The duration of efficacy was almost the same in the 2 groups.
4. Overall improvement was the same as improvement in VPC.
5. No significant difference was observed in the incidence of side effects. Five patients in the mexiletine group and 3 in the procainamide group reported side effects. The main side effect was light-headedness in the mexiletine group and a decrease in blood pressure in the procainamide group. A decrease in blood pressure was observed in 1 case in the mexiletine group but this was restored by an intravenous infusion of noradrenaline.
6. Mexiletine had little effect on blood pressure, while procainamide induced a drop in the systolic pressure. This difference was significant.
7. Overall utility ("markedly and moderately useful" , as judged by the subcommittee) was seen in 84.0% of the mexiletine group and 84.6% of the procainamide group. There was no significant difference between the 2 groups.
8. From the above results, it is concluded that mexiletine (3mg/Kg) is as efficacious as procainamide (10mg/Kg) in the treatment of VPC but that, unlike procainamide , mexiletine has little effect on blood pressure.
Additional Indexing Words: Ko 1173
Antiarrhythmic drug EXILETINE is an antiarrhythmic drug with local anesthetic activity that is in wide clinical trial in Western Europe for the treatment of ventricular premature contractions. Its efficacy has been reported in several studies.1)-6) It belongs to antiarrhythmic drug Class-Ib in the classification of Vaughan Williams et al, and has pharmacological properties similar to those of lidocaine.7)-9) Pharmacokinetically, however, unlike lidocaine, mexiletine has a long elimination half-life of 9-16 hrs, and is also effective when administered orally. 10) We have previously reported on its efficacy on ventricular premature contractions when administered as a single intravenous injection of 2, 3 or 4mg/ Kg.11) In the present study, procainamide, whose effectiveness has been well established, was selected as the control drug and a well-controlled comparative study was carried out in order to evaluate the efficacy, safety and usefulness of mexiletine.
SUBJECTS AND EXPERIMNTAL METHODS

I. Subjects
Inpatients or outpatients seen at the 12 participating facilities (Table I) were electrocardiographically monitored for 30min immediately prior to intravenous injection of test drugs. Those who showed a stable pattern of more than 5 ventricular premature contractions (VPC) per minute, particularly during the last 10min, were selected for the study. The subjects were all adults, and no particular restrictions were made in relation to sex or occupation. However, cases with the following were excluded : (1) serious cardiac failure, (2) serious conduction disturbances (atrioventricular block, sinoatrial block and bundle branch block) or bradycardia, (3) serious hepatic, renal and hematologic disorders, (4) excessive hypotension, (5) myasthenia gravis, (6) bronchial asthma, (7) collagen diseases, (8) Parkinsonism, (9) history of drug allergy, (10) pregnant women (including those in whom pregnancy was suspected, but unconfirmed), and (11) other cases judged by their doctors to be unsuitable for the study. The consent of each subject or of his guardian was obtained after the test procedures and the pharmacologic actions and possible side effects of the test drugs had been thoroughly explained.
II. Methods
1) Design
It is possible that during administration, intravenously injected antiarrhythmic drugs may unexpectedly induce a rapid drop in blood pressure or a serious arrhythmia such as a heart block requiring emergency treatment . In such a case, the treating physician should know the identity of the drug . In view of this, a double-blind design was considered to be inappropriate for this investigation. Instead, a well-controlled study using the envelope method was Jpn. HeartJ M ay 1984 employed. The investigations were carried out as follows. First, the investigator selected the next consecutively numbered envelope and administered the specified drug, either mexiletine or procainamide to the subject according to the instructions in the envelope which had been marked at random by the controller with a number indicating the order of opening. Then, clinical results, including the number of ventricular premature contractions, subjective symptoms and blood pressure before and after administration were entered in the case cards which were collected along with the serial electrocardiograms recorded during the study by the study subcommittee. Assessments of the efficacy of the drugs were made by both the investigators and the subcommittee, according to the criteria mentioned below. The subcommittee made their assessments on a blind basis as to the identity of the drug and any factors likely to affect judgement.
When all judgements had been made, a comparison of the efficacy of the two drugs was made after opening the key code in the presence of the controller. Decisions on exclusions and exceptions of cases were made by the persons concerned, including the controller, before opening the key code.
2) Drugs used in the investigation Although the mode of action of mexiletine appears to be most similar to that of lidocaine of all the intravenously administered antiarrhythmic drugs, lidocaine was considered to be inappropriate as a control drug because of the great differences in injection method and the duration of action between the two drugs. A single injection of mexiletine requires 10min while that of lidocaine, 1-2min; their elimination half-lives are 9-16 hrs and 1.5 hrs, respectively. The modes of action of diphenylhydantoin, procainamide and quinidine are rather similar to that of mexiletine, but procainamide was selected as the control drug because of its long and wide spread use and also because of the close similarity of its method of injection and its duration of efficacy to those of mexiletine. Procainamide was provided by Dai-ichi Seiyaku Co., Ltd.
An independent party (Prof. Koji Nagai, Hoshi Pharmaceutical College, Tokyo) certified that both drugs used were in conformity with their respective manufacturing specifications.
According to the results of our dose titration studies, a single intravenous injection of 3mg/Kg of mexiletine was considered to be the appropriate dose. For procainamide, a single intravenous injection of 10mg/Kg was selected because, judging from the blood level obtained after its intravenous administration, this dose appeared to be equipotent to 3mg/Kg of mexiletine, and because 10mg/Kg was regarded as within the usual therapeutic dosage in Vol.25 No.3 Japan.
3) Assignment of drugs (envelope method) After the random assignment of the drugs by the controller into groups of 8 cases each, directions for the administration of mexiletine or procainamide were placed consecutively numbered envelopes and distributed to all facilities. A master code was kept by the controller.
4) Administration method After the subjects had spent at least 30min quietly in bed, the test drugs were administered to them by single intravenous injection while their blood pressure and electrocardiogram were monitored. First, the investigator dissolved the mexiletine or procainamide in a saline or 5% glucose solution to a total volume of 20ml, which was then injected intravenously at a constant speed over a period of 10min. Electrocardiogram, blood pressure and other circulatory parameters were continuously monitored during and after intravenous injection, and the injection was discontinued if a serious side effect developed. In general, unless side effects such as a marked drop in blood pressure were observed, the total voume of test drug was injected, even if the arrhythmia disappeared completely during the injection. After this, the volume and the time (in minutes) of the injection were entered in a table.
Additional administration of mexiletine was not allowed, even if the efficacy of the test drug was seen to be insufficient, but instead, suitable alternative treatment was given. In such cases, the required observations were made for 1 hr and the details and time of the treatment were recorded.
5) Concomitant drugs
In principle, the following drugs were forbidden for 1 week before and 70min after the start of the study (1) antiarrhythmic drugs, (2) -receptor blocking agents, (3) calcium antagonists, (4) other drugs with antiarrhythmic action, (5) cardiac glycosides, (6) phenothiazines and tricyclic psychotropic drugs, (7) sympathomimetic agents, (8) sulfa drugs, (9) nonapproved drugs. The concomitant use of drugs was allowed provided they had no effect on arrhythmias, and that their name, method of usage, dosage and administration period were recorded.
6) Observation items a) Number of VPCs: The number of VPCs was calculated from electrocardiograms (lead II or its alternative) recorded continuously for 30min before and 1 hr after the end of the intravenous injection of the study drug. When consecutive premature contractions were recognized, their number was included in the total. A minimum paper speed of 25mm/sec was used during intravenous injection (10min) while speeds 1/5-1/10 of this were allowed during other periods as long as there were no problems in interpretation of Jpn. HeartJ M ay 1984 the electrocardiograms. Actual electrocardiograms were also required for submission to the subcommittee. b) Blood pressure: This was measured 5min before, immediately before, and every 2min after the start of intravenous injection , and then at the 2nd, 5th, 10th, 20th, 30th, 40th, 50th, and 60th min after the end of injection. c) Heart rate: This was measured before the start of injection, just after the end of injection and at the 10th, 20th, 30th, 40th, 50th, and 60th min after injection. d) Subjective symptoms: Subjective symptoms were observed by doctors at the times mentioned above and recorded. e) Laboratory data: Red and white blood cell and platelet counts, hemoglobin, hematocrit, Na, K, Cl, GOT, GPT, ALP, total bilirubin, total cholesterol, total protein, BUN, creatinine, urinary protein, urinary sugar and urobilinogen were measured before injection and, in general, within 24-48 firs after the end of injection. When abnormal results were obtained, followup and comments were required. f) Side effects: When side effects were induced by test drugs, the time of appearance, condition and progress of the patient, treatment methods and outcome were recorded. 7) Criteria for judgement of efficacy a) Investigator's judgement a-1) Improvement in VPC Number of VPC present in the periods from the start of injection to 5min after, from 5 to 10min after, from just after the end of injection to 10min after, and then from 10-20, 20-30, 30-40, 40-50, and 50-60min after injection were compared with the number recorded in the 10min just before injection, and the results were classified into 4 grades according to the following criteria:
(1) "marked improvement": a decrease in number of VPCs to 25% or less of that before injection, (2) "improvement": a decrease to 50% or less, (3) "no change": a decrease of less than 50% or an increase to less than double, and (4) "worse": an increase of more than double the baseline level.
VPC improvement was arbitrarily evaluated on a 5 step scale on the basis of the total progress over the whole observation period, as follows: (1) "marked improvement" , (2) "moderate improvement", (3) "slight improvement", (4) "no change", and (5) "worse".
a-2) Improvement in subjective symptoms Subjective symptoms after intravenous injection were compared with those before injection and evaluated according to the following 6 grades:
(1) "marked improvement", (2) "moderate improvement", (3) "slight im- provement", (4) "no change", (5) "worse", and (6) "no subjective symptoms during the study". a-3) Overall improvement Overall efficacy based on reduction in number of VPC and change in subjective symptoms was evaluated according to the following 5 grades: (1) "marked improvement" , (2) "moderate improvement", (3) "slight improvement", (4) "no change", and (5) "worse".
a-4) Overall safety Side effects and laboratory data (including hemodynamic data) were judged as a whole and evaluated according to the following 4 grades: (1) "no side effects" , (2) "slight side effects" (neither discontinuation of medication nor treatment required due to the side effect), (3) "moderate side effects" (discontinuation of medication due to side effects but no treatment required), and (4) "serious side effects" (some treatment required). a-5) Overall utility The overall efficacy and safety, together with clinical judgement based on previous experience, were considered and evaluated according to the following 5 grades: (1) "markedly useful", (2) "moderately useful", (3) "slightly useful" , (4) "neither useful nor useless", and (5) "useless". b) Judgement by the subcommittee The subcommittee consisted of representatives of the persons in charge of the examination. According to the criteria listed in Table II , the subcommittee objectively evaluated the improvement in VPC of each case, overall improvement, safety and utility on the basis of data obtained (including actual electrocardiograms).
The subcommittee members were unaware of the identity of the drugs used, the volume of the intravenous injection, the judgements of the investigators, the names of the hospitals, doctors and patients, which, it was considered, might affect their judgement.
8) Analysis methods
The Chi-square test, Mann-Whitney U-test (U-test), Fisher's exact probability test and Student's t-test were employed at 5% level of significance (two-tailed).
REULTS 1) Subjects
The test drugs were administered to 56 cases (Table III) in the order of the assigned numbers. Of these 56, 4 cases-viz, 3 with 50 or fewer VPC beats in the 10min before intravenous injection, and 1 with unstable VPC for 30min before injection-were excluded. One case, who received only 2/3 of the prescribed quantity of drug due to hypodermic leakage, was also excluded. Table IV shows how these cases were dealt with. Twenty-five cases in the mexiletine group and 26 in the procainamide group were analyzed for efficacy and utility whereas overall safety was assessed in 28 cases in the mexiletine group and in 27 in the procainamide group, since the exceptions were included in the safety evaluation.
2) Backgrounds of the subjects The backgrounds of the 55 subjects whose results were analyzed are shown in Table V . No significant difference in background was recognized between the 2 groups, and these were therefore considered to be equal for practical purposes.
3) Effects on VPC Both drugs showed their initial effect within 5min after the start of intravenous injection, with the greatest effect being observed in either the first or second 5min of injection or in the ensuing 10min after the end of injection Analysis of the total 56 cases including 1 omission also showed no significant difference in backgrounds between the 2 groups.
( Fig. 1) . Improvement in VPC during each time period is shown in improvement, 1 with no change and none became worse. In the procainamide group, there were 20 cases (76.9%) of marked improvement, 2 (7.7%) of moderate improvement, 1 (3.8%) of slight improvement, 2 with no change, and 1 which became worse. Thus, no significant difference was recognized between the groups. Six cases with 5 or more ventricular couplets in the 10min just before intravenous injection were observed in the mexiletine group, and there were 4 such cases in the procainamide group (Fig. 2) . Case No. 8-1 in the mexiletine group showed both ventricular couplets and triplets and whereas the latter disappeared within an hour, the former did not change. In all other cases, ventricular couplets disappeared or decreased. 4) Effects on subjective symptoms Since only 9 cases with subjective symptoms at baseline in the mexiletine group and only 2 such cases in the procainamide group were observed, no statistical analysis was made (Table VIII) .
The main symptoms were palpitaion, an irregular pulse and an oppressive sensation in the chest. In the mexiletine group, there were 3 cases (33.3%) of marked improvement, 3 cases (33.3%) of moderate improvement and 2 cases (22 .2%) of slight improvement, while in the procainamide group, 1 case (50.0%) showed marked improvement and 1 case (50.0%) slight improvement . ()=cumulative %; excluding those with no symptoms at baseline.
5) Overall improvement
The judgements of the subcommittee are shown in Table IX . The results were the same as those of degrees of improvement in VPC and no significant difference was observed between the 2 groups. 6) Overall safety Overall safety as judged by the subcommittee is shown in Table X . No significant differences in the incidence of side effects were observed between the 2 groups. Types of side effects are shown in Table XI . The main side effects were light-headedness (4 cases) in the mexiletine group and a drop in blood pressure (3 cases) in the procainamide group. Paresthesias of the tongue (2 cases) and a drop in blood pressure (1 case) were also observed in the mexiletine group. A serious side effect was observed in one subject in the J pn. HeartJM ay 1984 Table IX . Overall Improvement (Subcommittee) ()=cumulative %; N.S.=not significant. mexiletine group. This patient, who was suffering from ischernic heart disease with a slight depression of cardiac function and with cardiomegaly (CTR 58%), complained of light-headedness beginning about 6min after the start of intravenous injection, and experienced nausea, vomiting, facial pallor and a cold sweat possibly due to a drop in blood pressure about 5-6min later. At the same time, an intravenous infusion of noradrenaline was started. This was terminated after 15min, when the blood pressure was restored . 7) Effects on blood pressure and heart rate Since the blood pressure before intravenous injection differed between the 2 groups, the percentage changes in the blood pressure before intravenous injection (the mean of the pressure just before injection and that 5min before injection) are shown in Fig. 3 . A decrease in the systolic pressure was observed in the procainamide group but there was no change in the mexiletine group. From 2min after the start of intravenous injection until 5min after the end, a significant decrease in blood pressure (p<0.05-p<0.001) was observed in the procainamide group compared with that in the mexiletine group. No change in diastolic pressure was recognized in either group. The absolute values of the drop in blood pressure from baseline are shown in Table XII . The results are similar to those shown in Fig. 3 , namely, a significant decrease in systolic pressure was observed in the procainamide group compared with that in the mexiletine group (U-test, z=4.017, p<0.001, Fisher's exact probability test, p<0.001).
No significant changes in heart rate were observed as shown in Fig. 4 .
8) Laboratory data
The laboratory data before and after intravenous injection were compared with regard to blood count, serum electrolytes, hepatic and renal functions, urinary tests and CTR. No clinically significant changes due to test drugs were noted in either group. ()=cumulative %; N.S.=not signifcat.
9) Overall utility
The assessments of the subcommittee are shown in Table XIII . No significant difference was observed between the 2 groups. In the mexiletine group, there were 19 cases (76.0%) in which the drug was considered markedly useful, 2 (8%) moderately useful, 2 (8%) slightly useful and 2 (8%) useless, while in the procainamide group, the figures were 20 cases (76.9%), 2 (7.7%), 1 (3.8%), and 3 (11.5%), respectively.
DISCUION
Mexiletine belongs to antiarrhythmic drug Class-Ib according to Vaughan Williams' classification. It slows the phase of rapid depolarization (0-phase) of the action potential and shortens its duration in Purkinje fibers.7)-9) There have been many reports on the clinical efficacy of mexiletine in ventricular arrhythmias.1)-6),16),11) Trimarco et also have reported on the effect of intravenous mexiletine on stable ventricular arrhythmias in patients hospitalized in the CCU, while Horowitz et al5) have reported on its effect on ventricular arrhythmias developing within 48 hours of the onset of an acute myocardial infarction. They demonstrated in a comparative study that the efficacy of a 24-hour continuous intravenous infusion of mexiletine was the same as or superior to that of lidocaine and also that mexiletine was effective against ventricular arrhythmias resistant to lidocaine .
The clinical efficacy of a single intravenous injection of mexiletine was compared with that of procainamide in a well-controlled study , following dose titration studies.11) As noted above in the section on methodology , we considered procainamide to be more suitable than lidocaine as a control drug for the comparison of efficacy of a single injection because the injection time Jpn. HeartJM ay 1984 and the elimination half-lives of mexiletine and lidocaine were very different, in spite of their similarity in mode of action. Electrocardiograms were recorded continuously for a total of 100min, viz, 30min before intravenous injection as a control to certify the stability of VPC, 10min during injection and 60min after injection. The observation period after injection was based on the fact that the effective blood levels of the two drugs are maintained on the average for 60min.4),11)-14) In evaluating the results of these tests, the subcommittee made an objective judgement separately from the treating physicians. The judgement of the treating physicians on VPC improvement, overall improvement and utility was almost the same as that of the subcommittee (Table XIV) . Evaluation of overall safety by the treating physicians was identical to that by the subcommittee. From the above results, no significant difference was recognized between the 2 groups-that is, effectiveness for VPC ("marked and moderate degree") according to the subcommittee's judgement was seen in 88.0% 22/25 cases) in the mexiletine group and 84.6% (22/26 cases) in the procainamide group. In the latter, there was 1 case which became worse. No significant difference was observed between the 2 groups in changes with time of the number of VPCs or of ventricular couplets or triplets. This was also the case in the improvement of VPC during each time period. The effectiveness rate in the mexiletine group coincided roughly with the results from our dose titration studies (3mg/Kg: effective in 89%)11) or that of Waleffe et al (250mg: effective in 75%),17) while that in the procainamide group coincided roughly with that of Hayakawa et al (500mg: effective in 88.9%).18) Overall improvement (according to the subcommittee's judgement) was the same as improvement in VPC because there were few cases with subjective symptoms at baseline and none in whom VPC was unchanged showed improvement only in subjective symptoms. No significant difference in the incidence of side effects was observed between the groups: 5/28 cases (17.9%) in the mexiletine group and 3/27 cases (11.1%) in the procainamide group. Most side effects were so mild that they did not need special treatment. However, 1 case in the mexiletine group showed an obvious decrease in blood pressure, which was restored by intravenous infusion of noradrenaline. This patient had depressed cardiac function noted in various cardiac examinations performed prior to the study. It is considered that such cases should be carefully medicated, and this properly applies to the administration of antiarrhythmic drugs in general. The main side effect in the mexiletine group was light-headedness, while that in the procainamide was a decrease in blood pressure. Also, in our dose titration study of mexiletine, mild side effects, presumably due to its action on the central nervous system, were recognized. Neither drug had any effect on heart rate. On the other hand, many cases in the procainamide group showed a drop in blood pressure, especially in systolic pressure, while all cases in mexiletine group except one showed almost negligible changes. A significant difference in systolic blood pressure between the drugs was noted from 2min after the start of intravenous injection until 5min after the end of it. Both drugs showed little effect on diastolic blood pressure. Accordingly, mexiletine, unlike procainamide, has little effect on blood pressure. This view coincides with the reports by Shaw et al, 19) ,20) Pozenel,21) Utaka et al, 22) and Arakawa et al.11) In the clinical laboratory tests, no clinically significant changes due to the test drugs were observed.
No significant difference in overall utility, as judged by the subcommittee, was recognized between the 2 groups: in the mexiletine group, there were 19/25 cases (76.0%) in which the drugs was judged to be markedly useful and 21/25 cases (84.0%) moderately useful or more, while in the procainamide group, the figures were 20/26 cases (76.9%) and 22/26 cases (84.6%), respectively. Consequently, the efficacy of mexiletine (3mg/Kg) on ventricular premature contractions is considered to be similar to that of procainamide (10mg/Kg).
In the mexiletine group, 1 case was omitted, because 1/3 of the quantity of drug to be injected intravenously leaked into the subcutaneous tissue (Table IV ) (in this case the judgement of both the treating physicians and the subcommittee was marked improvement in both the degree of improvement in VPC and that of overall improvement; no side effects; and markedly useful). A painless swelling appeared at the injection site but disappeared in 2-3 days without sequelae.
